Axsome Therapeutics (AXSM) Income towards Parent Company (2022 - 2025)
Historic Income towards Parent Company for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$47.2 million.
- Axsome Therapeutics' Income towards Parent Company rose 2689.24% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 2619.57%. This contributed to the annual value of -$287.2 million for FY2024, which is 2005.45% down from last year.
- Per Axsome Therapeutics' latest filing, its Income towards Parent Company stood at -$47.2 million for Q3 2025, which was up 2689.24% from -$47.9 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Income towards Parent Company registered a high of -$11.2 million during Q1 2023, and its lowest value of -$98.6 million during Q4 2023.
- In the last 4 years, Axsome Therapeutics' Income towards Parent Company had a median value of -$61.2 million in 2022 and averaged -$57.9 million.
- As far as peak fluctuations go, Axsome Therapeutics' Income towards Parent Company soared by 7164.41% in 2023, and later crashed by 50826.66% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Income towards Parent Company stood at -$61.2 million in 2022, then tumbled by 61.06% to -$98.6 million in 2023, then increased by 24.05% to -$74.9 million in 2024, then soared by 36.95% to -$47.2 million in 2025.
- Its Income towards Parent Company was -$47.2 million in Q3 2025, compared to -$47.9 million in Q2 2025 and -$59.4 million in Q1 2025.